Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |6 June 2000

Using a Pregnancy-Related Hormone, Relaxin, to Treat Scleroderma

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled “Recombinant Human Relaxin in the Treatment of Scleroderma. A Randomized, Double-Blind, Placebo-Controlled Trial.” It is in the 6 June 2000 issue of Annals of Internal Medicine (volume 132, pages 871-879). The authors are J.R. Seibold, J.H. Korn, R. Simms, P.J. Clements, L.W. Moreland, M.D. Mayes, D.E. Furst, N. Rothfield, V. Steen, M. Weisman, D. Collier, F.M. Wigley, P.A. Merkel, M.E. Csuka, V. Hsu, S. Rocco, M. Erikson, J. Hannigan, W.S. Harkonen, and M.E. Sanders.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Scleroderma is a disease of unknown cause that produces fibrosis (hardening or scarring) of the connective tissue in the skin, blood vessels, and internal organs. This results in a tight, shiny appearance of the skin and potentially life-threatening abnormalities of the lungs, heart, kidneys, and digestive tract. Scleroderma can be mild or severe and there is no current effective treatment. Relaxin is a pregnancy-related hormone that blocks the development of fibrous tissue, so some experts suspect it might be useful in treating diseases, such as scleroderma, where fibrosis is a problem.

Why did the researchers do this particular study?

To find out if relaxin could be useful in treating patients who have scleroderma.

Who was studied?

68 patients who had had moderate to severe scleroderma for less than 5 years.

How was the study done?

Each study patient was randomly assigned to get a low dose (25 [g/kg of body weight per day] or a high dose (100 µg/kg of body weight per day) of relaxin, or placebo. Relaxin was given continuously from a pump through a needle placed under the skin, for a total of 24 weeks. The placebo looked like the relaxin and was given using the same type of pump but contained no active ingredient. The researchers then measured how severely each person's skin was affected by scleroderma using an accepted scoring system. They also did special tests of lung function, hand motion, and ability to perform tasks of daily living.

What did the researchers find?

Patients who got the lower dose of relaxin had significantly better skin scores than those who got placebo. All other measures also suggested benefit from the lower dose of relaxin. In contrast, patients who got the higher dose of relaxin did no better than those who got placebo. Side effects related to relaxin were mild and included heavy menstrual bleeding, anemia or low red blood counts, and irritation or infection at the site where the needle entered the skin.

What were the limitations of the study?

This study does not tell us whether this therapy would help patients with less severe scleroderma or those who have had the disease longer than 5 years. The study also does not tell us the effects of relaxin treatment for more than 24 weeks or whether the disease gets worse again after the low dose of relaxin is stopped.

What are the implications of the study?

Relaxin at a dose of 25 µg/kg of body weight per day may be an effective option for treating patients with moderate to severe scleroderma who have had their disease for less than 5 years.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

Not Available
Citations
Citation

Using a Pregnancy-Related Hormone, Relaxin, to Treat Scleroderma. Ann Intern Med. 2000;132:871. doi: https://doi.org/10.7326/0003-4819-132-11-200006060-00034

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2000;132(11):871.

DOI: 10.7326/0003-4819-132-11-200006060-00034

©
2000 American College of Physicians
0 Citations

See Also

Recombinant Human Relaxin in the Treatment of Scleroderma: A Randomized, Double-Blind, Placebo-Controlled Trial
View MoreView Less

Related Articles

Recombinant Human Relaxin in the Treatment of Scleroderma: A Randomized, Double-Blind, Placebo-Controlled Trial
Annals of Internal Medicine; 132 (11): 871-879
Annals for Educators - 21 August 2018
Annals of Internal Medicine; 169 (4): ED4
Menopausal Hormone Therapy: Summary of a Scientific Workshop
Annals of Internal Medicine; 138 (4): 361-364
New Treatments for Growing Scourge of Brittle Bones
Annals of Internal Medicine; 140 (2): 153-156
View MoreView Less

Journal Club

Guideline: Recommendations are provided for antiretroviral therapies in pregnant women with HIV
Annals of Internal Medicine; 168 (4): JC14
Guided early deescalation of antiplatelet treatment was noninferior to usual prasugrel care in PCI-treated ACS
Annals of Internal Medicine; 167 (12): JC69
Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non–insulin-treated type 2 diabetes
Annals of Internal Medicine; 167 (8): JC46
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events
Annals of Internal Medicine; 167 (6): JC28
View MoreView Less

Related Point of Care

Palliative Care
Annals of Internal Medicine; 168 (5): ITC33-ITC48
Clostridioides difficile Infection
Annals of Internal Medicine; 169 (7): ITC49-ITC64
Systemic Lupus Erythematosus
Annals of Internal Medicine; 159 (7): ITC4-1
Polymyalgia Rheumatica
Annals of Internal Medicine; 166 (9): ITC65-ITC80
View MoreView Less

Related Topics

Endocrine and Metabolism
Rheumatology
Scleroderma

Endocrine and Metabolism, Rheumatology, Scleroderma.

PubMed Articles

Cardiovascular health and vascular age after severe preeclampsia: A cohort study.
Atherosclerosis 2019;
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×